Tvardi Therapeutics (LTS:0HTC) Marketable Securities : £0.00 Mil (As of Mar. 2025)

View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Tvardi Therapeutics's Marketable Securities for the quarter that ended in Mar. 2025 was £0.00 Mil.

Tvardi Therapeutics's annual Marketable Securities increased from . 20 (£0.00 Mil) to Dec. 2022 (£18.27 Mil) but then declined from Dec. 2022 (£18.27 Mil) to Dec. 2023 (£0.00 Mil).

Tvardi Therapeutics Marketable Securities Historical Data

The historical data trend for Tvardi Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Marketable Securities Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Marketable Securities

18.27

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Sep24	Mar25
Marketable Securities	18.27	-	-	-	-

Tvardi Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Tvardi Therapeutics (LTS:0HTC) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Tvardi Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

TVRD:USA 69C:Germany

Address

3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines